Rare diseases
Investigational molecules
Locations
3 Bala Plaza East Suite 506, 19004-3481, United States
Larimar Therapeutics Inc. focuses on Friedreich’s ataxia, a rare, progressive multisystem disease affecting movement and neurological function. Its clinical research is centered on improving motor ability in both adults and children living with this condition.
The sponsor’s trial activity is directed toward movement-related outcomes in a genetic disorder linked to FXN deficiency.
Larimar Therapeutics Inc. runs clinical trials in conditions such as Friedreich's ataxia, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
A Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Nomlabofusp in Adults and Children with Friedreich’s Ataxia
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
